A New Way to Treat Hepatitis C

  • Author: Melania Tesio
  • Published: 25 August 2014
  • Copyright: Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim
  • Source / Publisher: Journal of General Virology/Society for General Microbiology
thumbnail image: A New Way to Treat Hepatitis C

Hepatitis C is a serious disease that can lead to liver failure or liver cancer. The current antiviral drugs block hepatitis C virus (HCV) replication and improve patient outcome, but cause strong side effects and are expensive, thus calling for alternatives.

Mark Douglas, University of Sydney (Westmead Hospital), Australia, and colleagues discovered that HCV replication can be blocked using AM251 (pictured above), a selective antagonist of cannabinoid 1 receptors (CB1). These proteins are present on the surface of liver cells where they regulate the metabolism of lipids. The researchers demonstrated that CB1 inhibition by AM251 reduced the viral replication in vitro by interfering with the synthesis of lipids.

CB1 antagonists may, therefore, represent a novel class of drugs to treat hepatitis C.


Article Views: 4685

Sign in Area

Please sign in below

Additional Sign In options

Please note that to comment on an article you must be registered and logged in.
Registration is for free, you may already be registered to receive, e.g., the newsletter. When you register on this website, please ensure you view our terms and conditions. All comments are subject to moderation.

Article Comments - To add a comment please sign in

If you would like to reuse any content, in print or online, from ChemistryViews.org, please contact us first for permission and consult our permission guidance prior to making your request

Follow on Facebook Follow on Twitter Follow on YouTube Follow on LinkedIn Follow on Instagram RSS Sign up for newsletters

Magazine of Chemistry Europe (16 European Chemical Societies) published by Wiley-VCH